Veraxa Biotech AG
Research Veraxa Biotech AG (VRXA) on Bullrun: market cap USD 35.10M, P/E 5.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVRXA
- ExchangeNASDAQ
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 35.10M
- P/E5.9
- Financial periodFY2025
- RevenueUSD 23.43K
- Net income-USD 66.61M
- Free cash flow-USD 10.34M
- Gross margin66.0%
Valuation Snapshot
latest market cap is USD 35.10M; P/E is 5.9.
Peer valuation comparison
Latest P/E is 5.9x versus a Healthcare sector median of 21.74x (72.9% below).
Latest P/E is 5.9x versus a Germany median of 15.62x (62.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 23.43K | -USD 66.61M | -USD 10.34M | 66.0% | n/a | USD 1.61M | USD 2.14M | -USD 15.77M |
| FY2024 | USD 0 | -USD 28.13M | -USD 7.84M | n/a | -0.2 | USD 5.36M | USD 864.49K | USD 31.05M |
| FY2023 | USD 0 | -USD 16.54M | -USD 7.50M | n/a | -0.12 | USD 11.35M | USD 0 | USD 55.13M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 35.10M | 5.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 337.44M | 57.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 316.88M | 76.5 | n/a | n/a |
About Veraxa Biotech AG
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Veraxa Biotech AG's market cap?
Veraxa Biotech AG's market capitalization is USD 35.10M.
What is Veraxa Biotech AG's P/E ratio?
Veraxa Biotech AG's price-to-earnings (P/E) ratio is 5.9.
What does Veraxa Biotech AG do?
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.